We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Foghorn Therapeutics Inc | NASDAQ:FHTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.49 | 8.89% | 6.00 | 5.85 | 6.00 | 6.03 | 5.61 | 5.61 | 188,804 | 23:13:41 |
From May 2023 to May 2024
By Colin Kellaher
Foghorn Therapeutics shares rose sharply in premarket trading Monday after the clinical-stage biotechnology company said the U.S. Food and Drug Administration has lifted a clinical hold on a study of its FHD-286.
The Cambridge, Mass., company said it expects to launch a Phase 1 study of FHD-286 in the third quarter.
Foghorn last August said the FDA had placed a full clinical hold on the Phase 1 monotherapy dose escalation study of FHD-286 in acute myelogenous leukemia and myelodysplastic syndrome due to suspected cases of fatal differentiation syndrome believed to be associated with FHD-286 treatment.
The company said it has amended the trial protocol, and that it now plans to study FHD-286 in combination with decitabine or cytarabine in relapsed and/or refractory acute myelogenous leukemia patients .
Foghorn shares, which closed Friday at $7.10, were recently up more than 18% to $8.40 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 05, 2023 07:52 ET (11:52 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Foghorn Therapeutics Chart |
1 Month Foghorn Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
